Since 2008, two other very promising therapeutic classes have been placed on the market: dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon like peptide 1 (GLP-1) analogues to promote insulin secretion without the risk of hypoglycemia. The gene discussed is INS; the disease is Hypoglycemia.